Showing results (581-590 of 634) with videos related to

Sort By:
Pageof 64
British Journal of Cancer|May 25, 2026
Silencing of NUP62 overcomes osimertinib resistance via ubiquitination of survivin in non-small cell lung cancer cellsSeok Soon Park, Hye Won Lee, Mi Ri Kwon, et al.
Cancer Research Communications|February 26, 2026
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results From the Phase 2 LEAP-005 StudyMariano Ponz-Sarvisé, Sun Young Rha, Carlos A Gomez-Roca, et al.
The Lancet. Oncology|April 4, 2021
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trialThierry Andre, Mayur Amonkar, Josephine M Norquist, et al.
Oncology|March 25, 2009
A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumorMin-Hee Ryu, Won Ki Kang, Yung-Jue Bang, et al.
International Journal of Molecular Sciences|June 19, 2024
Ibulocydine Inhibits Migration and Invasion of TNBC Cells via MMP-9 RegulationMi-Ri Kwon, Ji-Soo Park, Eun-Jung Ko, et al.
Nature Medicine|April 20, 2026
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trialIgnacio Melero, Tamara Tanos, Emiliano Calvo Aller, et al.
Cancer Science|July 30, 2021
Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancerSatoru Iwasa, Kei Muro, Satoshi Morita, et al.
Cancer Science|November 12, 2022
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancerTakayuki Yoshino, Thierry Andre, Tae Won Kim, et al.
Apoptosis : an International Journal on Programmed Cell Death|March 22, 2014
NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotypeSeung-Woo Hong, Jae-Sik Shin, Jai-Hee Moon, et al.
The Lancet. Oncology|October 16, 2012
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trialYong Sang Hong, Young Suk Park, Ho Yeong Lim, et al.
Pageof 64